At a glance
ClinicalIndex Comparison RecordPhase 2Active· 24 enrolled
Drug / intervention
PI3K-beta Inhibitor GSK2636771drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol N: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients With Tumors With PTEN Mutation or Deletion, With PTEN Expression on IHC
In Brief
A Phase 2 clinical trial evaluating PI3K-beta Inhibitor GSK2636771 for Advanced Lymphoma and 5 related conditions. Active but no longer recruiting, targeting 24 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial identifies the effects of GSK2636771 in patients whose cancer has a genetic change called PTEN mutation or deletion. GSK2636771 may block a protein called PI3K-beta, which may be needed for growth of cancer cells that express PTEN mutations. Researchers hope to learn if GSK2636771 will shrink this type of cancer or stop its growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
20172018201920202021202220232024202520262027
Enrollment StartMay 2016
First PostedJun 2020
Primary CompletionNov 2020
TodayJul 2026
Study CompletionDec 2026
First PostedJun 19, 2020
Enrollment StartMay 5, 2016
Primary CompletionNov 10, 2020
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 6.0 years ago
Interventions
PI3K-beta Inhibitor GSK2636771drug
Given PO